Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) issued its earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.07, Zacks reports.
Helix Biopharma Price Performance
Shares of OTCMKTS HBPCF remained flat at $0.77 during midday trading on Thursday. Helix Biopharma has a twelve month low of $0.77 and a twelve month high of $1.73. The firm has a 50-day moving average of $1.28 and a 200-day moving average of $1.61. The firm has a market capitalization of $58.81 million, a PE ratio of -19.25 and a beta of 0.11.
About Helix Biopharma
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.
Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth.
Read More
- Five stocks we like better than Helix Biopharma
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
